Matheus Epifane-De-Assunção
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matheus Epifane-De-Assunção has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Ândrea Ribeiro-Dos-Santos
Universidade Federal do Pará, Brazil
4 shared publications - Bruno Lopes Santos-Lobato
Laboratório de Neuropatologia Experimental, Universidade Federal do Pará, Belém, Brazil
3 shared publications - Gilderlanio Santana de Araújo
Universidade federal do Pará
3 shared publications - Giovanna Chaves Cavalcante
Departamento de Bioquímica, Instituto de Química, and Centro de Metabolismo CoMeta, Hospital Universitário, Universidade de São Paulo, São Paulo, Brazil
3 shared publications Ana Gabrielle Bispo
Laboratory of Human and Medical Genetics, Federal University of Pará, Belém, Brazil
2 shared publicationsCaio Santos Silva
Laboratory of Medical and Human Genetics, Institute of Biological Sciences, Federal University of Pará, 66075-110, Belém, Pará, Brazil
2 shared publications
Latest Publications
- Open Access
SlytheRINs: using graph parameters and residue interaction networks to analyze protein dynamics and structural ensembles
Establishing the relationship between protein structure and functional behavior remains a significant challenge. The recognition that proteins are inherently dynamic, with functions often dependent on conformational changes, is increasingly accepted. Among computational approaches for elucidating protein properties, Residue Interaction Network (RIN) analysis has emerged as a powerful tool. However, conventional RIN analysis is constrained by its reliance on single, static protein structures, which fail to capture the flexibility inherent in dynamic protein folding transitions. To address these limitations, SlytheRINs is introduced as an interactive tool designed for comparative analysis of protein conformations via RINs. SlytheRINs enables dynamic ensemble analysis by decomposing interaction network data across multiple conformations of a single protein and providing detailed residue-interaction mapping across conformational changes via graph parameters in comparative plots. Applying these principles, the conformational variations of the wild-type and a pathogenic variant (G188R) of the human Glucose-6-Phosphatase (G6PC1) catalytic subunit were compared to identify fluctuations in both chemical interactions and graph features associated with conformational changes induced by the residue modification. The analyses identified key shifts in dynamic residue interactions in the protein variant that compromise substrate binding and the catalytic site, thereby elucidating the impact on G6PC1’s dynamic behavior and the resulting activity loss. Availability: The source code for SlytheRINs is available on GitHub ( https://github.com/evomol-lab/SlytheRINs ), while the web tool and documentation are available at https://slytherins.streamlit.app .
Open AccessSlytheRINs: using graph parameters and residue interaction networks to analyze protein dynamics and structural ensembles
Establishing the relationship between protein structure and functional behavior remains a significant challenge. The recognition that proteins are inherently dynamic, with functions often dependent on conformational changes, is increasingly accepted. Among computational approaches for elucidating protein properties, Residue Interaction Network (RIN) analysis has emerged as a powerful tool. However, conventional RIN analysis is constrained by its reliance on single, static protein structures, which fail to capture the flexibility inherent in dynamic protein folding transitions. To address these limitations, SlytheRINs is introduced as an interactive tool designed for comparative analysis of protein conformations via RINs. SlytheRINs enables dynamic ensemble analysis by decomposing interaction network data across multiple conformations of a single protein and providing detailed residue-interaction mapping across conformational changes via graph parameters in comparative plots. Applying these principles, the conformational variations of the wild-type and a pathogenic variant (G188R) of the human Glucose-6-Phosphatase (G6PC1) catalytic subunit were compared to identify fluctuations in both chemical interactions and graph features associated with conformational changes induced by the residue modification. The analyses identified key shifts in dynamic residue interactions in the protein variant that compromise substrate binding and the catalytic site, thereby elucidating the impact on G6PC1’s dynamic behavior and the resulting activity loss. Availability: The source code for SlytheRINs is available on GitHub ( https://github.com/evomol-lab/SlytheRINs ), while the web tool and documentation are available at https://slytherins.streamlit.app .
- Open Access
- 20 February 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 145, 108250
Mitochondrial insertions/deletions (INDELs) burden in Parkinson's disease: an analysis from a Brazilian cohort
- 20 February 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 145, 108250
Open AccessMitochondrial insertions/deletions (INDELs) burden in Parkinson's disease: an analysis from a Brazilian cohort
- Open Access
- 19 February 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 145, 108252
Molecular analysis of mitochondrial complex I in the levodopa short duration response in Parkinson's disease
- 19 February 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 145, 108252
Open AccessMolecular analysis of mitochondrial complex I in the levodopa short duration response in Parkinson's disease
- Open Access
Novel mitochondrial variants associated with Parkinson's disease reveal a high heteroplasmy-weighted polygenic risk score in Brazilians
Mitochondrial single-nucleotide variants (mtSNVs) can dysregulate cellular bioenergetics and have been increasingly implicated in susceptibility to Parkinson's disease (PD). These variants may impair oxidative metabolism and respiratory chain efficiency, thus contributing to neuronal dysfunction and degeneration. In peripheral blood, mtSNVs may also reflect systemic immunometabolic alterations associated with PD; however, this aspect remains poorly explored, particularly in admixed populations with significant indigenous ancestry. In this study, we analyzed the complete mtDNA of peripheral blood samples from 179 admixed individuals (104 with PD and 75 controls) from the Brazilian Amazon. Associations between mtSNVs and PD were assessed using adjusted logistic regression models, and functional annotation was performed using the Variant Effect Predictor. Furthermore, we proposed and calculated a heteroplasmy-weighted mitochondrial polygenic risk score (mtPRS). We observed a higher mtSNV burden in PD patients, predominantly in RNR2 gene and genes of Complexes I and IV. In total, 536 unique mitochondrial SNVs were identified (214 exclusive to PD, 321 shared between PD and controls, and one exclusive to controls). Four mitochondrial SNVs were associated with PD, including three novel variants (COX1: m.6630G>A, COX2: m.7613C>T, and RNR2: m.1996C>T) and one previously reported variant (ND4: m.12112C>T). Notably, the mitochondrial polygenic risk score (mtPRS) showed a strong association with increased PD risk (OR = 3.64; FDR = 1.12 x 10e-6). Taken together, these results suggest that mtSNVs may contribute to PD susceptibility in admixed Amazonian population, highlighting the relevance of mitochondrial genetic architecture in PD and emphasizing the importance of including underrepresented populations in genomic research.
Open AccessNovel mitochondrial variants associated with Parkinson's disease reveal a high heteroplasmy-weighted polygenic risk score in Brazilians
Mitochondrial single-nucleotide variants (mtSNVs) can dysregulate cellular bioenergetics and have been increasingly implicated in susceptibility to Parkinson's disease (PD). These variants may impair oxidative metabolism and respiratory chain efficiency, thus contributing to neuronal dysfunction and degeneration. In peripheral blood, mtSNVs may also reflect systemic immunometabolic alterations associated with PD; however, this aspect remains poorly explored, particularly in admixed populations with significant indigenous ancestry. In this study, we analyzed the complete mtDNA of peripheral blood samples from 179 admixed individuals (104 with PD and 75 controls) from the Brazilian Amazon. Associations between mtSNVs and PD were assessed using adjusted logistic regression models, and functional annotation was performed using the Variant Effect Predictor. Furthermore, we proposed and calculated a heteroplasmy-weighted mitochondrial polygenic risk score (mtPRS). We observed a higher mtSNV burden in PD patients, predominantly in RNR2 gene and genes of Complexes I and IV. In total, 536 unique mitochondrial SNVs were identified (214 exclusive to PD, 321 shared between PD and controls, and one exclusive to controls). Four mitochondrial SNVs were associated with PD, including three novel variants (COX1: m.6630G>A, COX2: m.7613C>T, and RNR2: m.1996C>T) and one previously reported variant (ND4: m.12112C>T). Notably, the mitochondrial polygenic risk score (mtPRS) showed a strong association with increased PD risk (OR = 3.64; FDR = 1.12 x 10e-6). Taken together, these results suggest that mtSNVs may contribute to PD susceptibility in admixed Amazonian population, highlighting the relevance of mitochondrial genetic architecture in PD and emphasizing the importance of including underrepresented populations in genomic research.
- Open Access
- 1 January 2024
- Published by Elsevier in SSRN Electronic Journal
Differential Gene Expression Analysis Supports Dysregulation of Mitochondrial Activity as a New Perspective for Glioblastoma's Aggressiveness
Brain cancer is considered one of the most aggressive and lethal types of cancer, including primary tumors, subdivided into milder forms such as low-grade gliomas and glioblastoma, considered the most aggressive form with metastasis. Among the hallmarks of glioblastoma, the deregulation of mitochondrial metabolism has not yet been fully elucidated. Therefore, the search for mitochondrial biomarkers that can be used as indicators of the progression of this type of cancer is necessary. The aim of this study was to investigate the difference in gene expression between astrocytoma-type gliomas and glioblastomas, and how genes involved in mitochondrial metabolism can influence the proliferative cascade and be associated with tumor invasion. From the differential analysis of glioblastoma expression when compared to the milder form, 11 differentially expressed genes were found in our study, six of which were upregulated (ATP5MGL, C15orf48, MCUB, TERT, AGXT and CYP27B1) and four downregulated (SLC2A4, GK2, SLC25A48, ETNPPL and HMGCS2). Among these genes, we highlight that none of them had been reported in glioblastoma until this research, and we suggest these genes as possible biomarkers, since they are associated with essential pathways for the tumor, such as glucose metabolization, gluconeogenesis, calcium and vitamin D metabolism, tumor progression and activation of the metastatic cascade.
- 1 January 2024
- Published by Elsevier in SSRN Electronic Journal
Open AccessDifferential Gene Expression Analysis Supports Dysregulation of Mitochondrial Activity as a New Perspective for Glioblastoma's Aggressiveness
Brain cancer is considered one of the most aggressive and lethal types of cancer, including primary tumors, subdivided into milder forms such as low-grade gliomas and glioblastoma, considered the most aggressive form with metastasis. Among the hallmarks of glioblastoma, the deregulation of mitochondrial metabolism has not yet been fully elucidated. Therefore, the search for mitochondrial biomarkers that can be used as indicators of the progression of this type of cancer is necessary. The aim of this study was to investigate the difference in gene expression between astrocytoma-type gliomas and glioblastomas, and how genes involved in mitochondrial metabolism can influence the proliferative cascade and be associated with tumor invasion. From the differential analysis of glioblastoma expression when compared to the milder form, 11 differentially expressed genes were found in our study, six of which were upregulated (ATP5MGL, C15orf48, MCUB, TERT, AGXT and CYP27B1) and four downregulated (SLC2A4, GK2, SLC25A48, ETNPPL and HMGCS2). Among these genes, we highlight that none of them had been reported in glioblastoma until this research, and we suggest these genes as possible biomarkers, since they are associated with essential pathways for the tumor, such as glucose metabolization, gluconeogenesis, calcium and vitamin D metabolism, tumor progression and activation of the metastatic cascade.
- Open Access
- 25 May 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (6) , 856
Identification of Genomic Variants Associated with the Risk of Acute Lymphoblastic Leukemia in Native Americans from Brazilian Amazonia
A number of genomic variants related to native American ancestry may be associated with an increased risk of developing Acute Lymphoblastic Leukemia (ALL), which means that Latin American and hispanic populations from the New World may be relatively susceptible to this disease. However, there has not yet been any comprehensive investigation of the variants associated with susceptibility to ALL in traditional Amerindian populations from Brazilian Amazonia. We investigated the exomes of the 18 principal genes associated with susceptibility to ALL in samples of 64 Amerindians from this region, including cancer-free individuals and patients with ALL. We compared the findings with the data on populations representing five continents available in the 1000 Genomes database. The variation in the allele frequencies found between the different groups was evaluated using Fisher’s exact test. The analyses of the exomes of the Brazilian Amerindians identified 125 variants, seven of which were new. The comparison of the allele frequencies between the two Amerindian groups analyzed in the present study (ALL patients vs. cancer-free individuals) identified six variants (rs11515, rs2765997, rs1053454, rs8068981, rs3764342, and rs2304465) that may be associated with susceptibility to ALL. These findings contribute to the identification of genetic variants that represent a potential risk for ALL in Amazonian Amerindian populations and might favor precision oncology measures.
- 25 May 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (6) , 856
Open AccessIdentification of Genomic Variants Associated with the Risk of Acute Lymphoblastic Leukemia in Native Americans from Brazilian Amazonia
A number of genomic variants related to native American ancestry may be associated with an increased risk of developing Acute Lymphoblastic Leukemia (ALL), which means that Latin American and hispanic populations from the New World may be relatively susceptible to this disease. However, there has not yet been any comprehensive investigation of the variants associated with susceptibility to ALL in traditional Amerindian populations from Brazilian Amazonia. We investigated the exomes of the 18 principal genes associated with susceptibility to ALL in samples of 64 Amerindians from this region, including cancer-free individuals and patients with ALL. We compared the findings with the data on populations representing five continents available in the 1000 Genomes database. The variation in the allele frequencies found between the different groups was evaluated using Fisher’s exact test. The analyses of the exomes of the Brazilian Amerindians identified 125 variants, seven of which were new. The comparison of the allele frequencies between the two Amerindian groups analyzed in the present study (ALL patients vs. cancer-free individuals) identified six variants (rs11515, rs2765997, rs1053454, rs8068981, rs3764342, and rs2304465) that may be associated with susceptibility to ALL. These findings contribute to the identification of genetic variants that represent a potential risk for ALL in Amazonian Amerindian populations and might favor precision oncology measures.